导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -0.04% | 1634/3266 |
| 近一周 | -1.93% | 2094/3690 |
| 近一月 | -0.26% | 501/3663 |
| 近一季 | -2.84% | 1043/3534 |
| 近半年 | -8.25% | 2368/3357 |
| 近一年 | 2.39% | 1562/3056 |
| 近两年 | 99.49% | 481/2167 |
| 近三年 | 60.88% | 343/1638 |
| 成立以来 | 200.16% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.28% 1328/4961 |
-1.45% 3351/5312 |
- - |
- - |
| 2025 | 39.39% 826/4813 |
8.09% 461/3635 |
8.80% 313/4076 |
13.71% 2971/4524 |
4.24% 553/4813 |
| 2024 | 6.76% 1724/3463 |
-11.59% 2435/2808 |
-11.13% 2507/3014 |
19.62% 823/3129 |
13.60% 139/3463 |
| 2023 | 32.56% 8/2656 |
21.68% 131/2280 |
6.25% 46/2385 |
-3.40% 919/2515 |
6.14% 27/2655 |
| 2022 | -6.58% 130/2207 |
-6.69% 224/1919 |
-0.06% 1591/2016 |
-6.74% 107/2113 |
7.43% 310/2208 |
| 2021 | 34.31% 50/1822 |
-2.13% 586/1255 |
16.20% 208/1330 |
3.88% 394/1466 |
13.68% 74/1822 |
| 2020 | 16.44% 776/1250 |
1.65% 142/1028 |
8.40% 824/1067 |
13.25% 334/1164 |
-6.70% 1147/1184 |
| 2019 | 42.73% 208/1092 |
38.53% 62/754 |
-8.99% 626/804 |
1.56% 388/850 |
11.46% 60/918 |
| 2018 | -27.19% 417/834 |
- - |
- - |
- - |
-4.39% 28/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 大成360互联网+大数据100C VS. 长安沪深300非周期A(740101) |